{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-24-000037","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.282344+00:00","generated_at":"2026-06-03T07:24:58.790340+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Edwards Q1 sales $1.6B (+10%), TMTT +75%; raises FY sales guidance to high end 8-10%","bullets":["Q1 sales $1.6B, up 10% reported and constant currency; GAAP EPS $0.58, adjusted EPS $0.66.","TAVR sales $1.0B (+6% reported, +8% constant currency adjusted for billing days).","TMTT sales $73M (+75%); EVOQUE received FDA approval for tricuspid regurgitation in Feb.","Full-year 2024 sales guidance raised to high end of 8-10% range; TMTT guidance raised to $320-340M.","Critical Care spin-off on track; full-year adjusted EPS guidance maintained at $2.70-$2.80."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-24-000037","json":"https://secwatch.observer/filing/0001099800-24-000037.json","markdown":"https://secwatch.observer/filing/0001099800-24-000037.md","text":"https://secwatch.observer/filing/0001099800-24-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980024000037/0001099800-24-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980024000037/ew-20240425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T07:24:58.790340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}